TG Therapeutics Receives Clearance from FDA for Phase 1 Trial in Multiple Sclerosis for Allogeneic CAR-T Azer-Cel
Azer-cel was originally developed by Precision BioSciences, but licensed to TG Therapeutics.
The FDA has cleared an investigational new drug (IND) application submitted by TG Therapeutics for azercabtagene zapreleucel (azer-cel), an investigational allogeneic chimeric antigen receptor T-cell (CAR-T) therapy, for a phase 1 clinical trial in patients with progressive multiple sclerosis (MS).1
Azer-cel was originally developed by Precision BioSciences, but licensed to TG Therapeutics for further development for the potential treatment of autoimmune diseases and other noncancer indications. In light of the IND clearance, TG Therapeutics now intends to initiate a phase 1 clinical trial before the end of the year.
“We would like to congratulate TG Therapeutics on receiving IND clearance for azer-cel in patients with progressive MS,” Michael Amoroso, MBA, the chief executive officer of Precision BioSciences, said in a statement.1 “We believe the expansion of allogeneic CAR-T into autoimmune diseases holds the potential to unlock new therapies for patients living with chronic disease. We look forward to TG Therapeutics initiating a clinical trial for azer-cel in autoimmune disease as we focus on the advancement of our own wholly owned in vivo gene editing pipeline, including our planned IND and/or clinical trial application submission for PBGENE-HBV for hepatitis B this year.”
Precision garnered an upfront payment and potential near-term economics valued at $17.5 million for the licensing of azer-cel to TG Therapeutics. In addition, the deal includes potential for up to $288 million in further milestone payment, as well as the potential for royalties.
Azer-cel is not the only cell therapy currently in development for the treatment of MS. Just earlier this month, the FDA
Another trial assessing a novel therapy for MS is IASO Bio’s
Kyverna Therapeutics is also exploring the potential of bringing
Precision BioSciences is directing its own efforts towards the advancement of in vivo gene therapy products based on its ARCUS platform. CGTLive®
REFERENCES
1. Precision BioSciences announces investigational new drug clearance by partner TG Therapeutics for investigation of azer-cel for multiple sclerosis. News release. Precision BioSciences, Inc. August 9, 2024. Accessed August 14, 2024. https://investor.precisionbiosciences.com/news-releases/news-release-details/precision-biosciences-announces-investigational-new-drug
2. Indapta Therapeutics Announces FDA Clearance of IND for Phase 1 Trial of IDP-023 for Progressive Multiple Sclerosis. News release. Indapta Therapeutics. August 6, 2024. https://www.businesswire.com/news/home/20240806112913/en/Indapta-Therapeutics-Announces-FDA-Clearance-of-IND-for-Phase-1-Trial-of-IDP-023-for-Progressive-Multiple-Sclerosis
3. IASO Bio Receives U.S. FDA Approval of Investigational New Drug Application for EquecabtageneAutoleucel for Multiple Sclerosis. News release. IASO Bio. July 23, 2024. https://www.prnewswire.com/news-releases/iaso-bio-receives-us-fda-approval-of-investigational-new-drug-application-for-equecabtagene-autoleucel-for-multiple-sclerosis-302204711.html
4. Fischbach F, Richter J, Pfeffer LK, et al. CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosis. Med. Published online March 29, 2024. doi: 10.1016/j.medj.2024.03.002
5. Lewis W, Owens G, Jordan-Steele M, et al. ARCUS-mediated excision of the “hot spot” region of the human dystrophin gene for the treatment of Duchenne muscular dystrophy (DMD). Presented at: American Society of Gene and Cell Therapy (ASGCT) 2023 Annual Meeting. May 16-20, 2023; Los Angeles, CA.
Newsletter
Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.
Related Articles
- ImmunoLogic, Episode 6: "The Future of Personalized Cancer Vaccines”
September 15th 2025
- Top News in Lymphoma Cell Therapy for World Lymphoma Awareness Day 2025
September 15th 2025
- Duchenne Action Month 2025: Looking Back at News and Expert Insights
September 14th 2025
- CGTLive®’s Weekly Rewind – September 12, 2025
September 12th 2025